Transaction DateRecipientSharesTypePriceValue
20th October 2020Michelle Kumbier162Grant/award etc.$0.00
12th October 2020Roxanne S Austin8,000Open or private sale$149.23$1,193,840.00
5th October 2020Roxanne S Austin2,000Open or private sale$145.73$291,460.00
1st October 2020Roxanne S Austin10,000Open or private sale$141.13$1,411,300.00
1st October 2020Roxanne S Austin30,000Open or private sale$140.50$4,215,000.00
1st October 2020Roxanne S Austin40,000Open or private sale$144.99$5,799,600.00
1st October 2020Gregory A Ahlberg1,490Grant/award etc.$0.00
1st October 2020Roxanne S Austin10,000Open or private sale$145.49$1,454,900.00
30th September 2020Andrea F Wainer30,000Exercise of derivative$38.40$1,152,000.00
30th September 2020Andrea F Wainer30,000Open or private sale$107.01$3,210,360.00
Abbott Laboratories
Abbott Laboratories logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 2/10.


Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Cardiovascular and Neuromodulation Products, and Other.


Ticker: ABT
Sector: Healthcare
Industry: Medical Devices
SEC Central Index Key (CIK): 1800
Employees: 107000
Exchange: New York Stock Exchange
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $5 B (23%)
Inventory, Net: $5 B (20%)
Assets, Current: $17 B (9%)
Property, Plant and Equipment, Net: $8 B (3%)
Assets: $69 B (1%)
Short-term Debt: $205 M (1%)
Long-term Debt, Current Maturities: $1 B (1%)
Liabilities, Current: $11 B (0%)
Long-term Debt, Excluding Current Maturities: $18 B (9%)
Common Stock, Value, Issued: $24 B (0%)
Common Stock, Shares, Issued: $2 B (0%)
Retained Earnings (Accumulated Deficit): $26 B (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $9 B (0%)
Stockholders' Equity (Parent): $31 B (-1%)
Liabilities and Equity: $69 B (1%)
Revenue: $7 B (0%)
Cost of Revenue: $3 B (-50%)
Research and Development: $564 M (-50%)
Operating Income/Loss: $672 M (-53%)
Provision for income taxes: $11 M (-85%)
EPS (basic): $0.3 (-51%)
EPS (diluted): $0.3 (-50%)